Propylene Glycol-Containing Peptide Formulations Which Are Optimal For Production And For Use In Injection Devices

Patent No. EP1687019 (titled "Propylene Glycol-Containing Peptide Formulations Which Are Optimal For Production And For Use In Injection Devices") was filed by Novo Nordisk on Nov 18, 2004. The application was issued on Nov 22, 2017.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (6)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP1687019

NOVO NORDISK
Application Number
EP04797453A
Filing Date
Nov 18, 2004
Status
Opposition Rejected
Jan 20, 2023
Publication Date
Nov 22, 2017